Core Insights - Fagron has strengthened its leadership in the EMEA region through acquisitions in Poland and Hungary, aligning with its strategy to diversify in dynamic markets and emphasizing its disciplined M&A approach for sustainable growth [1][2][8] Acquisitions - The acquisitions of Amara in Poland and Magilab in Hungary are expected to contribute mid-teens (€m) in annual revenue with an EBITDA margin exceeding Fagron's existing group margin, with a combined purchase price of approximately €26 million [2][4][5] - Amara brings over 30 years of experience in the Polish compounding sector and enhances Fagron's offerings while unlocking significant synergy potential [4] - Magilab is a trusted brand in Hungary's hospital pharmacy segment, consolidating Fagron's position in a market characterized by high compounding per capita [5] Financial Developments - Fagron has secured a new U.S. dollar credit facility totaling up to $225 million with maturities extending up to 15 years, enhancing financial flexibility and supporting growth ambitions in North America [6] - An initial $125 million has been drawn from this facility, which complements an existing €575 million bank facility [6] Licensing and Market Presence - Fagron has received a license for its Fagron Sterile Services facility in Boston, allowing the shipment of compounding medication to California, a significant step in reinforcing its presence in a major U.S. healthcare market [3][7] - This license enables all of Fagron's 503B facilities in the U.S. to ship to California, unlocking further opportunities with key customers [7] Strategic Vision - The CEO of Fagron highlighted that the acquisitions and financial developments are crucial for consolidating leadership in EMEA and supporting global ambitions in the B&E segment [8][9] - The company emphasizes its commitment to disciplined M&A, operational excellence, and prudent balance sheet management as key enablers of sustained growth and long-term success [10]

Group 1 - Fagron completed a share buy-back program, repurchasing a total of 200,000 shares at an average price of €20.6805, amounting to €4,136,093 [1][2] - The recent buy-back occurred from 10 November 2025 to 14 November 2025, during which 44,000 shares were bought at an average price of €20.7208, totaling €911,717 [1] - The buy-back program was announced on 9 October 2025, and the repurchased shares will be used to meet obligations under Fagron's long-term incentive scheme [2] Group 2 - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to hospitals, pharmacies, clinics, and patients in over 35 countries [4] - The company is based in Nazareth, Belgium, and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [5] - Operational activities are managed through Fagron BV, which is headquartered in Rotterdam [5] Group 3 - The financial calendar includes key dates such as the full year results for 2025 on 12 February 2026 and the trading update for the first quarter of 2026 on 9 April 2026 [3]

Group 1 - Fagron has initiated a share buy-back program, purchasing 20,000 shares at an average price of €20.609, totaling €412,180 from 16 October 2025 to 17 October 2025 [1] - The share buy-back program aims to fulfill obligations under Fagron's long-term incentive scheme, with a total of up to 200,000 shares planned for repurchase [1] - To date, Fagron has purchased a total of 20,000 shares under this program [1] Group 2 - Fagron is a global leader in pharmaceutical compounding, providing personalized medicine to hospitals, pharmacies, clinics, and patients in over 30 countries [3] - The company is registered in Belgium and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4] - Operational activities are managed by Fagron BV, headquartered in Rotterdam, Netherlands [4]

Core Insights - Fagron reported a solid third-quarter performance with a revenue growth of 6.4%, reaching €228.2 million, and confirmed its full-year revenue outlook of €930 – €950 million for 2025 [1][6][7] Group 1: Financial Performance - The company achieved an organic growth rate of 8.5% at constant exchange rates (CER) on a normalized basis, and 5.7% when accounting for the impact of GLP-1 drug shortages [7] - Revenue for Q3 2025 was €228.2 million, reflecting a 6.4% increase and a 10.3% increase at CER, driven by resilient structural drivers and focused commercial execution [7] Group 2: Regional Performance - EMEA showed broad-based progress across Brands, Essentials, and Compounding Services, with a mix of mature and growth markets responding positively to commercial efforts [3] - Latin America, particularly Brazil, continued strong momentum with targeted commercial activities and product launches supporting increased adoption [4] - North America remains a key growth engine, with planned capacity expansion and successful FDA inspections validating corrective actions [4] Group 3: M&A Activity - The company maintained momentum in mergers and acquisitions (M&A), signing University Compounding Pharmacy to strengthen its health and wellness platform in the U.S. [5] - Antitrust clearance for Purifarma and Injeplast in Brazil marks a significant milestone for expanding Fagron's portfolio and capabilities [5] - A total of eight acquisitions have been announced year-to-date, indicating ongoing strategic growth initiatives [7]

Core Viewpoint - Fagron has received Brazilian antitrust clearance for the acquisitions of Purifarma and Injeplast, marking a significant advancement in its M&A strategy in Latin America [1][2]. Group 1: Acquisitions and Strategic Importance - The acquisitions of Purifarma and Injeplast will enhance Fagron's portfolio and capabilities in Brazil, aligning with the company's long-term growth objectives [2]. - Purifarma's large-scale operations in Essentials present substantial potential for profitability improvements within 18 months post-closing through product portfolio expansion and operational efficiencies [3]. - Injeplast will enhance Fagron's vertical integration by providing high-quality packaging solutions, thereby broadening the product portfolio and customer base in Latin America and other regions [4]. Group 2: Management Commentary - CEO Rafael Padilla emphasized that the approvals from CADE facilitate the closing of the acquisitions, reinforcing Fagron's leadership in Brazil and supporting its strategy of combining targeted M&A with operational excellence while maintaining financial discipline [5]. Group 3: Company Overview - Fagron is a leading global company in pharmaceutical compounding, delivering personalized medicine across more than 35 countries [6]. - The company is based in Nazareth, Belgium, and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [7].

Core Viewpoint - Fagron has announced the acquisition of University Compounding Pharmacy (UCP) in North America, which will enhance its presence in the pharmaceutical compounding market, particularly in the health and wellness segment [1][3][4]. Group 1: Acquisition Details - The enterprise value of the acquisition is approximately $41.5 million, fully financed through Fagron's own resources, and is subject to customary clearance [5]. - UCP specializes in hormones and urology, and has a strong compliance record, making it a complementary addition to Fagron's existing operations [3][4]. - The acquisition is expected to generate around $25 million in annual revenue, with an EBITDA margin below Fagron's existing group margin, and synergies are anticipated over the next 18–24 months [5]. Group 2: FDA Inspection Update - Fagron's facilities in Wichita and Las Vegas were inspected by the FDA, with no repeated observations from the 2024 inspection in Wichita, indicating successful remediation of prior concerns [2][6]. - Following a new routine inspection, the FDA issued a Form 483 with six observations for Fagron Sterile Services and four observations for the 503B Anazao Health facility in Las Vegas [7]. - The company is committed to addressing the FDA's inspectional observations and is implementing corrective actions to enhance its protocols [8].

Group 1 - Fagron received a notification from Mawer Investment Management Ltd regarding a change in shareholding, specifically crossing the disclosure threshold of 5% downwards [1][6] - On 29 August 2025, Mawer Investment Management Ltd held a total of 3,632,837 voting rights, which represented 4.96% of the total voting rights based on a denominator of 73,313,904 [6] - The notification indicates that the change in shareholding was due to the disposal of voting securities or voting rights [6] Group 2 - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to various healthcare facilities in over 35 countries [3] - The company is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4] - Fagron's operational activities are managed through its Dutch subsidiary, Fagron BV, which is headquartered in Rotterdam [4]

Core Points - Fagron received a notification from Alychlo NV regarding a change in shareholding that crossed the disclosure threshold of 3% downwards [1][8] - The notification indicates that Alychlo NV disposed of voting securities or voting rights on 25 July 2024, resulting in a new holding of 2,139,886 voting rights [8] - The total number of voting rights at that time was 73,228,904, meaning Alychlo NV and Marc Coucke together held 2.93% of the total voting rights [8] Company Information - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to hospitals, pharmacies, clinics, and patients in over 30 countries [3] - The company is registered in Nazareth and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4] - Operational activities are managed by Fagron BV, headquartered in Rotterdam [4]

Group 1 - Fagron has issued 85,000 new shares as a result of the exercise of subscription rights on June 6, 2025 [1] - The total share capital of Fagron currently amounts to €504,303,905.59, with a total of 73,313,904 shares with voting rights [2] - There are 1,465,833 rights to subscribe to not yet issued shares with voting rights [2] Group 2 - Fagron is a leading global company in pharmaceutical compounding, providing personalized medicine to various healthcare facilities in 35 countries [3] - The company is registered in Nazareth and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [4] - Fagron's operational activities are managed by its Dutch subsidiary, Fagron BV, headquartered in Rotterdam [4]

Group 1 - Fagron held its annual general shareholders meeting where all voting items were approved [1] - The meeting approved Fagron's annual financial statements and a dividend proposal of €0.35 per share for the fiscal year 2024 [2] - The remuneration policy and the appointment of the statutory auditor for the financial years 2025 to 2027 were also approved [2] Group 2 - Ann Desender BV was reappointed as independent non-executive director until the annual general meeting of 2029 [2] - All meeting documents are available on Fagron's website, including the minutes of the meetings [3] - Fagron operates in over 30 countries, focusing on personalized medicine for hospitals, pharmacies, clinics, and patients [4] Group 3 - Fagron NV is registered in Nazareth and listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR' [5] - The operational activities are managed by Fagron BV, headquartered in Rotterdam [5] Group 4 - The dividend calendar includes an ex-dividend date of 19 May 2025, record date of 20 May 2025, and payment date of 21 May 2025 [7]